Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Patten

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Nature Communications|January 4, 2024
A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potentialGregory H Bird, J J Patten, William Zavadoski, et al.
Biorxiv : the Preprint Server for Biology|April 15, 2024
Single-cell image-based genetic screens systematically identify regulators of Ebola virus subcellular infection dynamicsRebecca J Carlson, J J Patten, George Stefanakis, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 8, 2004
Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversibleDavid M Stresser, Marc I Broudy, Thuy Ho, et al.
Antiviral Research|August 8, 2024
Amidino-rocaglates (ADRs), a class of synthetic rocaglates, are potent inhibitors of SARS-CoV-2 replication through inhibition of viral protein synthesisPatrick T Keiser, Wenhan Zhang, Michael Ricca, et al.
Nature Microbiology|July 24, 2025
Single-cell image-based screens identify host regulators of Ebola virus infection dynamicsRebecca J Carlson, J J Patten, George Stefanakis, et al.
Nature Cancer|November 5, 2021
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancerPeter M K Westcott, Nathan J Sacks, Jason M Schenkel, et al.
Journal of Medical Virology|September 19, 2022
Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapyRuthMabel Boytz, Mikołaj Słabicki, Sita Ramaswamy, et al.
Iscience|April 25, 2023
The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope proteinCharles Zou, Hojong Yoon, Paul M C Park, et al.
Nature Genetics|September 14, 2023
Mismatch repair deficiency is not sufficient to elicit tumor immunogenicityPeter M K Westcott, Francesc Muyas, Haley Hauck, et al.
Biorxiv : the Preprint Server for Biology|April 28, 2021
Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivoJ J Patten, Patrick T Keiser, Deisy Gysi, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Nature Communications|January 4, 2024
A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potentialGregory H Bird, J J Patten, William Zavadoski, et al.
Biorxiv : the Preprint Server for Biology|April 15, 2024
Single-cell image-based genetic screens systematically identify regulators of Ebola virus subcellular infection dynamicsRebecca J Carlson, J J Patten, George Stefanakis, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 8, 2004
Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversibleDavid M Stresser, Marc I Broudy, Thuy Ho, et al.
Antiviral Research|August 8, 2024
Amidino-rocaglates (ADRs), a class of synthetic rocaglates, are potent inhibitors of SARS-CoV-2 replication through inhibition of viral protein synthesisPatrick T Keiser, Wenhan Zhang, Michael Ricca, et al.
Nature Microbiology|July 24, 2025
Single-cell image-based screens identify host regulators of Ebola virus infection dynamicsRebecca J Carlson, J J Patten, George Stefanakis, et al.
Nature Cancer|November 5, 2021
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancerPeter M K Westcott, Nathan J Sacks, Jason M Schenkel, et al.
Journal of Medical Virology|September 19, 2022
Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapyRuthMabel Boytz, Mikołaj Słabicki, Sita Ramaswamy, et al.
Iscience|April 25, 2023
The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope proteinCharles Zou, Hojong Yoon, Paul M C Park, et al.
Nature Genetics|September 14, 2023
Mismatch repair deficiency is not sufficient to elicit tumor immunogenicityPeter M K Westcott, Francesc Muyas, Haley Hauck, et al.
Biorxiv : the Preprint Server for Biology|April 28, 2021
Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivoJ J Patten, Patrick T Keiser, Deisy Gysi, et al.
Pageof 9